Follow-up Study to Evaluate the Long-term Immunogenicity and Safety of a HPV Vaccine (580299) in Healthy Female Subjects
Subjects were aged 10-14 years at the time of entry into the primary study. No vaccine will
be administered in this extension study.
Results on outcome measures describing analyses on other studies are not reported in this
record. Please refer to the records mentioned in the respective outcome measure titles.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers
Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).
at Month 60
GSK Clinical Trials